The Immunomodulators Market is on the cusp of exponential growth, with forecasts predicting an increase from roughly USD 217.7 billion in 2023 to an estimated USD 388.7 billion by 2032. This significant rise, characterized by an impressive compound annual growth rate (CAGR) of 6.7%, is largely
The gene therapy sector, once a beacon of hope for revolutionary treatments, has seen a significant slowdown in investment post the COVID-19 pandemic. This downturn follows a period of unprecedented financial influx during the pandemic years, raising questions about the future of this promising
South Korea's pharmaceutical and biotech industry is witnessing a fascinating shift as Contract Development and Manufacturing Organizations (CDMOs) and biosimilar developers are experiencing robust growth, while traditional pharmaceutical companies lag. At the forefront of this transition is
In October 2023, Sanofi, a leading global pharmaceutical company, announced a major shift in its business strategy. This shift involved the separation of its consumer health division, a move set to be completed in 2024. Historically, Sanofi's consumer health division, which includes popular
Fujifilm Diosynth Biotechnologies, a leading CDMO in the field of biologics, vaccines, advanced therapies, and oncolytic viruses, has embarked on the initial phase of a massive expansion project at their facility in Hillerød, Denmark. By adding six mammalian cell bioreactors to the existing
October 2024 saw a surge in biotech investments, with notable contributions from companies across North America, Europe, and the Asia-Pacific regions. Major players like Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics secured substantial funding, reflecting the growing
